Background

Breast cancer is the most common and lethal malignant tumor among women worldwide, accounting for approximately 22% of all malignancies in women (Hashim et al. 2016). The incidence of breast cancer has increased nearly 10-fold over the past 10 years (Siegel et al. 2016). At present, surgical resection is still the main treatment for breast cancer patients in early stage accompanied by adjuvant chemotherapy (Lee and Chu 2018; Feng et al. 2018). Identification of new sensitive diagnosis biomarkers is crucial for the efficacy of chemotherapy for breast cancer. However, due to migration and invasion of breast cancer cells, metastasis becomes the main reason for treatment failure (Benson et al. 2009). Therefore, although comprehensive treatment modes have gradually reduced the death rate of breast cancer patients (Albuquerque et al. 2018), there is still a considerable necessary to continuously explore the molecular mechanism of breast cancer occurrence and metastasis and search for potential intervention targets.

Tissue factor pathway inhibitor 2 (TFPI2) is a proteolytic enzyme inhibitor with a Kunitz domain, and belongs to the superfamily of serine protease inhibitors (Chand et al. 2004). TFPI2 could inhibit extracellular matrix hydrolysis via suppression of matrix metalloproteinases (Herman et al. 2001). Recently, studies have shown that TFPI2 is down-regulated in prostate cancer (Konduri et al. 2001), pancreatic ductal adenocarcinoma (Sato et al. 2005), gastric cancer (Takada et al. 2010), non-small-cell lung cancer (Rollin et al. 2005), etc., and is closely related to various malignant tumors progression. Down-regulation of TFPI2 was found to be associated with poor survival in patients with breast cancer (Xu et al. 2013). CpG methylation in the promoter of TFPI2 inhibits binding ability between Kruppel-like factor 6 (KLF6) and TFPI2 in breast cancer (Guo et al. 2007). However, the effect and mechanism involved in the regulation of TFPI2 on breast cancer have not been reported.

TWIST1 belongs to basic helix-loop-helix transcription factor family, and functions as promoter of epithelial-to-mesenchymal transition, cell migration and invasion in cancer cells (Khan et al. 2013). TWIST1 promotes breast cancer cell migration and invasion via different signaling pathways (Xu et al. 2017a; Glackin 2014). Therefore, we hypothesized that the potential regulatory mechanism of TFPI2 on breast cancer dependents on TWIST1. We first investigated the expression level of TFPI2 in breast cancer, and the down-regulation of TFPI2 was regarded as the starting point to further discuss the function and mechanism of TFPI2 in the occurrence and development of breast cancer.

Methods

Patient samples and immunohistochemistry

Fifty surgical cancer specimens from breast cancer patients and 16 normal breast tissues were collected at The Second Affiliated Hospital of Dalian Medical University. The study was approved by the Ethics Committee of The Second Affiliated Hospital of Dalian Medical University, and all the patients signed written informed consent. Paraffin-embedded breast cancer tissues were cut into 5 μm thick sections. The sections were then dewaxed and rehydrated following by antigens retrieval and endogenous peroxidase blocking. After blocking with 2% goat serum in PBS, sections were then incubated overnight with primary rabbit antibodies against TFPI2 and TWIST1 (Abcam, Cambridge, MA, USA). HRP (horseradish peroxidase, Sigma Aldrich, St. Louis, MO, USA)-conjugated goat anti-rabbit IgG secondary antibody was then added, and the slides were counterstained with hematoxylin and examined under light microscope (Olympus, Tokyo, Japan).

Cell culture

Human breast cancer cell lines (MDA-MB-453, MDA-MB-468 and MCF7), breast fibroblast cell line (CCD-1095Sk) and non-tumorigenic epithelial cell line (MCF10A) were purchased from Chinese Academy of Sciences (Shanghai, China), and cultured in Ham’s F12K (Gibco; Thermo Fisher, Waltham, MA, USA) supplemented with 10% fetal bovine serum at 37 °C constant temperature incubator with 5% CO2.

Cell transfection

pcDNA3.1-TFPI2, pcDNA3.1-TWIST1 and the negative control (pcDNA3.1-NC) were obtained from AxyBio co., LTD (Changsha, China). shRNAs targeting TFPI2 (shTFPI2#1, #2, #3) or shTWIST1 and the negative control (shNC) were synthesized by GenePharma (Shanghai, China). 1 × 106 cells/well of MDA-MB-453, MCF7 or MCF10A cells were seeded into 12-well plate and then transfected with pcDNA3.1-TFPI2, pcDNA3.1-TWIST1 andpcDNA3.1-NC or shTFPI2#1, #2, #3 and shNC via Lipofectamine® 3000 (Thermo Fisher, Waltham, MA, USA). Two days after transfection, the cells were collected for the following experiments.

Cell proliferation assay

5 × 103 cells/well MDA-MB-453 or MCF10A cells were seeded in 96-well plate. At 0, 1, 2, 4, 6 days, 20 μL CCK8 solution (Dojindo, Tokyo, Japan) was added into each well and mixed for 3 h. Microplate Autoreader (BioTek, Winooski, VT, USA) was used to measure optical density at 450 nm. For colony formation experiments, MDA-MB-453 or MCF10A cells were seeded on six-well plate with 200 cells/well and cultured with Ham’s F12K. Fourteen days later, the cells were fixed in formalin and stained with crystal violet (0.1%). The visible colonies were counted and photographed under light microscope.

Wound healing and Transwell assay

For cell migration analysis, MDA-MB-453 or MCF10A cells were seeded in 6-well plates. Wound gap in the cell monolayer was generated by scratching with plastic pipette tip. The cells were washed with PBS to remove debris or the detached cells, and then cells were cultured in Ham’s F12K for another 48 h before calculating the wound width. For cell invasion analysis, MDA-MB-453 cells were seeded into the upper wells of chamber (Corning, MA, USA) with the Matrigel-coated membrane (BD Biosciences, Franklin Lakes, NJ, USA) in serum-free Ham’s F12K. Ham’s F12K with 10% FBS were added to the lower wells. The medium of upper wells and the filters were removed 8 h later. The invasive cells to the bottom of chambers were fixed with 100% methanol and then stained with 0.1% crystal violet 24 h later, imaged and counted under microscope.

Quantitative real-time PCR (qRT-PCR)

Total RNAs from normal breast tissues, breast cancer tissues or cell lines were extracted via RNeasy Mini Kit (Qiagen, Manchester, UK). Complementary DNAs were then generated by PrimeScript RT Reagent (Takara, Shiga, Japan). qRT-PCR was analyzed by ViiA 7 (Applied Biosystems, Austin, TX, USA), and the relative expression of indicated genes were normalized to GAPDH and calculated using 2-△△Ct methods. The primer sequences were listed in primer Table 1.

Table 1 Primer sequences
Full size table

Western blot

30 μg proteins extracted from normal breast tissues, breast cancer tissues or cell lines were separated by sodium dodecyl sulfate-polyacrylamide gelelectrophoresis, and then transferred to nitrocellulose membrane (Millipore, Bedford, MA). The membranes were blocked by 5% skimmed milk and then incubated overnight with primary antibodies, including anti-TFPI2 antibodies (1:1500, Abcam), TWIST (1:2000, Abcam), integrin α5 (1:2500, Abcam), GAPDH (1:3000, Abcam) at 4 °C. Lastly, the immunoreactivities were detected by enhanced chemiluminescence (KeyGen, Nanjin, China) after incubating with HRP labeled secondary antibody (1:5000; Abcam).

Mouse xenograft assay

Animal experiments were approved by the Ethics Committee of The Second Affiliated Hospital of Dalian Medical University. Twelve-seven weeks old female BALB/c nude mice were used and conducted in accordance with the National Institutes of Health Laboratory Animal Care and Use Guidelines. Ad-pcDNA 3.1-TFPI2 and the negative control (Ad-pcDNA 3.1-NC), were constructed by GenePharma (Shanghai, China). 100 μL of 2.5 × 106 MDA-MB-453 cells transfected with Ad-pcDNA 3.1-TFPI2 or Ad-pcDNA 3.1-NC were injected into mice mammary fat pad. Tumors were measured and the volume was calculated at 7, 10, 14, 17, 21, 24 days. Twenty- four days later, mice were anesthetized with sodium pentobarbital at 65 mg per kg body weight, and the breast cancer tissues were collected for analysis.

Statistical analysis

The data were shown as mean ± standard deviation, and the statistics analysis was performed by the SPSS 19.0 (SPSS, Chicago, IL). Student’s t text was used to compare the difference between two groups, one-way ANOVA with Turkey’s test to compare the difference among multiple groups. p < 0.05 was considered as statistically significant.

Results

TFPI2 was down-regulated in breast cancer tissues and cell lines

The expression of TFPI2 was first investigated in breast cancer tissues and cell lines. The results showed that the expression of TFPI2 in breast cancer was lower than in normal breast specimens (Fig. 1a). In addition, immunohistochemistry also showed that TFPI2 expression was negatively correlated to metastatic property of breast cancer. The results demonstrated thatmetastatic breast cancer tissues had the lowest expression of TFPI2, while non-metastatic breast cancer tissues showed higher and normal breast tissues presented the highest expression of TFPI2 (Fig. 1b). Therefore, TFPI2 may contribute to breast cancer progression. Further refinement analysis of correlation between TFPI2 and clinic pathologic characteristics of breast cancer patients indicated that among the 50 patients, low expression of TFPI2 (N = 25) was significantly related to tumor size (P = 0.005), metastasis (P = 0.018) and pathological stage (P = 0.010) (Table 2), suggesting the potential of TFPI2 as a prognostic biomarker for breast cancer. However, age (P = 0.777) and nodal status (P = 0.156) showed no significant correlation with TTFPI2 expression (Table 2). Consistent with expression in breast cancer tissues, TFPI2 was also down-regulated in human breast cancer cell lines (MDA-MB-453, MDA-MB-468 and MCF7) compared to breast fibroblast cell line (CCD-1095Sk) and MCF10A (Fig. 1c). MDA-MB-453 cell with lowest expression of TFPI2 was selected for the following gain-of functional assays, and MCF7 was selected for loss-of functional assay.

Fig. 1
figure 1

TFPI2 was down-regulated in breast cancer tissues and cell lines. a The expression of TFPI2 was down-regulated in breast cancer (Tumor) compared to normal breast specimens (Normal). ** represents Tumor vs. Normal tissues, P < 0.01. b Immunohistochemistry of TFPI2 in Normal, Non-metastasis or metastasis breast cancer tissues, suggesting down-regulation of TFPI2 in breast cancer tissues. c The expression of TFPI2 was down-regulated in human breast cancer cell lines (MDA-MB-453, MDA-MB-468 and MCF7) compared to CCD-1095Sk and MCF 10A. *, ** represents breast cancer cell lines vs. CCD-1095Sk, P < 0.05, P < 0.01

Full size image
Table 2 Relationship between TFPI2 mRNA and clinico-pathological parameters
Full size table

Over-expression of TFPI2 suppressed cell viability, proliferation, migration and invasion of breast cancer

Gain-of functional assays were conducted via transfection of pcDNA 3.1-TFPI2 into MDA-MB-453 cell to determine the effects of TFPI2 on breast cancer proliferation. Over-expression efficiency was confirmed in mRNA (Fig. 2a) and protein (Fig. 2b) levels. CCK8 (Fig. 2c) and colony formation assay (Fig. 2d) results indicated that over-expression of TFPI2 deceased cell viability and inhibited cell proliferation of MDA-MB-453 cells, suggesting the anti-proliferative ability of TFPI2 on breast cancer. Wound healing (Fig. 3a) and transwell (Fig. 3b) assays showed that over-expression of TFPI2 suppressed cell migration and invasion of MDA-MB-453 cells, suggesting the anti-invasive ability of TFPI2 on breast cancer. MCF10A cells were also transfected with pcDNA 3.1-TFPI2 (Supplemental Figure S1B). Over-expression of TFPI2 significantly decreased cell viability (Supplemental Figure S1C), while had no significant effect on cell proliferation (Supplemental Figure S1D). Moreover, cell migration (Supplemental Figure S1E) and invasion (Supplemental Figure S1F) were also not significantly affected by TFPI2 over-expression.

Fig. 2
figure 2

Over-expression of TFPI2 suppressed cell viability and proliferation of breast cancer. a Up-regulation of TFPI2 in MDA-MB-453 cells transfected with pcDNA 3.1-TFPI2 indicated by qRT-PCR. ** represents pcDNA 3.1-TFPI2 (TFPI2) vs. pcDNA 3.1-NC (NC), p < 0.01. b Up-regulation of TFPI2 in MDA-MB-453 cells transfected with pcDNA 3.1-TFPI2 detected by western blot. c Over-expression of TFPI2 inhibited cell viability of MDA-MB-453 cells. ** represents pcDNA 3.1-TFPI2 vs. pcDNA 3.1-NC, p < 0.01. d Over-expression of TFPI2 inhibited cell proliferation of MDA-MB-453 cells. * represents pcDNA 3.1-TFPI2 vs. pcDNA 3.1-NC, p < 0.05

Full size image
Fig. 3
figure 3

Over-expression of TFPI2 suppressed migration and invasion of breast cancer. a Over-expression of TFPI2 inhibited cell migration of MDA-MB-453 cells. ** represents pcDNA 3.1-TFPI2 vs. pcDNA 3.1-NC, p < 0.01. b Over-expression of TFPI2 inhibited cell invasion of MDA-MB-453 cells. ** represents pcDNA 3.1-TFPI2 vs. pcDNA 3.1-NC, p < 0.01

Full size image

TFPI2 regulated TWIST1 expression in breast cancer

Since TWIST1 has been reported to be involved in progression of breast cancer, the effect of TFPI2 on TWIST1 expression was determined in breast cancer. Knockdown of TFPI2 in MCF7 cells via shRNAs transfection was demonstrated in Fig. 4a. In addition, transfection with shRNAs in CCD-1095Sk, MDA-MB-453 and MDA-MB-468 cells also reduced the mRNA expression of TFPI2 (Supplemental Figure S1A). Meanwhile, shTFPI2#3 with the lowest expression of TFPI2 was selected for the following loss-of functional assays and named as shTFPI2. Western blot analysis indicated that TWIST1 was decreased in MDA-MB-453 cells transfected with pcDNA-3.1 TFPI2, while increased in MCF7 cells transfected with shTFPI2 (Fig. 4b), suggesting the negative correlation between TFPI2 and TWIST1 in breast cancer. Moreover, integrin α5 is the downstream target of TWIST1 which can regulate invasion of tumors (Nam et al. 2015). Consistent with expression of TWIST1 in MDA-MB-453 cells, the expression of integrin α5 was also decreased by pcDNA-3.1 TFPI2 and up-regulated by shTFPI2 (Fig. 4b), suggesting TWIST1/integrin α5 axis in regulation of breast cancer progression. Immunohistochemistry results showed up-regulation of TWIST1 in breast cancer tissues (Fig. 4c), and a significantly negative correlation between TFPI2 and TWIST1 in breast cancer was determined via bivariate correlation analysis (Fig. 4d).

Fig. 4
figure 4

TFPI2 regulated TWIST1 expression in breast cancer. a Down-regulation of TFPI2 in MCF7 cells transfected with shTFPI2#1. #2, #3 indicated by qRT-PCR. ** represents shTFPI2#1. #2, #3 vs. shNC, p < 0.01. b Over-expression of TFPI2 inhibited protein expression of TWIST1 and integrin α5, while inhibition of TFPI2 promoted TWIST1 and integrin α5. c Immunohistochemistry of TWIST1 in Normal and Tumor breast cancer tissues, suggesting up-regulation of TWIST1 in tumor tissues. d Negative correlation TFPI2 and TWIST1 in breast cancer patients

Full size image

Inhibition ability of TFPI2 on breast cancer progression was reversed by TWIST1 over-expression

To establish the effect of TFPI2/TWIST1 axis on breast cancer progression, MDA-MB-453 cells were cotransfected with pcDNA 3.1-TFPI2 and pcDNA 3.1-TWIST1. mRNA expression of TWIST1 was decreased in cells transfected with pcDNA 3.1-TFPI2, while reversed in cells cotransfected with pcDNA 3.1-TFPI2 and pcDNA 3.1-TWIST1 (Fig. 5a). CCK8 (Fig. 5b) and colony formation (Fig. 5c) assays showed that the inhibition ability of TFPI2 on breast cancer cell proliferation was promoted by additional transfection of pcDNA 3.1-TWIST1. Moreover, results from cell migration (Fig. 5d) and invasion (Fig. 5e) analysis indicated that the suppression abilities of TFPI2 on cell migration and invasion were restored in cells cotransfected with pcDNA 3.1-TFPI2 and pcDNA 3.1-TWIST1. All these results revealed that the inhibition effect of TFPI2 on breast cancer progression was reversed by TWIST1 over-expression, which confirmed the effect of TFPI2/TWIST1 axis on regulation of breast cancer progression. The down-regulation of TWIST1 protein expression by TFPI2 over-expression was also reversed by additional over-expression of TWIST1 (Fig. 5f). Moreover, MCF7 cells were also cotransfected with pcDNA 3.1-TFPI2 and shTWIST1. However, cotransfection with pcDNA 3.1-TFPI2 and shTWIST1 had no significant effect on cell viability (Fig. 5g), protein expression of TWIST1 and integrin α5 (Fig. 5h), cell proliferation (Fig. 5i), cell migration (Fig. 5j) and invasion (Fig. 5k) compared to cells cotransfected pcDNA 3.1-NC with shTWIST1.

Fig. 5
figure 5

Inhibition ability of TFPI2 on breast cancer progression was reversed by TWIST1 over-expression. a The mRNA expression of TWIST1 was decreased in cells transfected with pcDNA 3.1-TFPI2, while reversed in cells cotransfected with pcDNA 3.1-TFPI2 and pcDNA 3.1-TWIST1. ** represents pcDNA 3.1-TFPI2 vs. pcDNA 3.1-NC or pcDNA 3.1-TFPI2 + pcDNA 3.1-TWIST1 vs. pcDNA 3.1-TFPI2 + pcDNA 3.1-NC, p < 0.01. b pcDNA 3.1-TFPI2 inhibited cell viability of MDA-MB-453 cells, while cotransfection with pcDNA 3.1-TFPI2 and pcDNA 3.1-TWIST1 promoted the cell viability. ** represents pcDNA 3.1-TFPI2 vs. pcDNA 3.1-NC or pcDNA 3.1-TFPI2 + pcDNA 3.1-TWIST1 vs. pcDNA 3.1-TFPI2 + pcDNA 3.1-NC, p < 0.01. c Transfection with pcDNA 3.1-TFPI2 inhibited cell proliferation of MDA-MB-453 cells, while cotransfection with pcDNA 3.1-TFPI2 and pcDNA 3.1-TWIST1 promoted the cell proliferation. ** represents pcDNA 3.1-TFPI2 vs. pcDNA 3.1-NC or pcDNA 3.1-TFPI2 + pcDNA 3.1-TWIST1 vs. pcDNA 3.1-TFPI2 + pcDNA 3.1-NC, p < 0.01. d Transfection with pcDNA 3.1-TFPI2 inhibited cell migration of MDA-MB-453 cells, while cotransfection with pcDNA 3.1-TFPI2 and pcDNA 3.1-TWIST1 promoted the cell migration. ** represents pcDNA 3.1-TFPI2 vs. pcDNA 3.1-NC or pcDNA 3.1-TFPI2 + pcDNA 3.1-TWIST1 vs. pcDNA 3.1-TFPI2 + pcDNA 3.1-NC, p < 0.01. e Transfection with pcDNA 3.1-TFPI2 inhibited cell invasion of MDA-MB-453 cells, while cotransfection with pcDNA 3.1-TFPI2 and pcDNA 3.1-TWIST1 promoted the cell invasion.. ** represents pcDNA 3.1-TFPI2 vs. pcDNA 3.1-NC or pcDNA 3.1-TFPI2 + pcDNA 3.1-TWIST1 vs. pcDNA 3.1-TFPI2 + pcDNA 3.1-NC, p < 0.01. f Protein expression of TWIST1 and integrin α5 were down-regulated in cells transfected with pcDNA 3.1-TFPI2, while up-regulated in cells cotransfected with pcDNA 3.1-TFPI2 and pcDNA 3.1-TWIST1. g Cotransfection with pcDNA 3.1-TFPI2 and shTWIST1 had no significant effect on cell viability of MCF7 cells compared to cells cotransfected pcDNA 3.1-NC with shTWIST1. h Cotransfection with pcDNA 3.1-TFPI2 and shTWIST1 had no significant effect on protein expression of TWIST1 and integrin α5 in MCF7 cells compared to cells cotransfected pcDNA 3.1-NC with shTWIST1. i Cotransfection with pcDNA 3.1-TFPI2 and shTWIST1 had no significant effect on cell proliferation of MCF7 cells compared to cells cotransfected pcDNA 3.1-NC with shTWIST1. j Cotransfection with pcDNA 3.1-TFPI2 and shTWIST1 had no significant effect on cell migration of MCF7 cells compared to cells cotransfected pcDNA 3.1-NC with shTWIST1. k Cotransfection with pcDNA 3.1-TFPI2 and shTWIST1 had no significant effect on cell invasion of MCF7 cells compared to cells cotransfected pcDNA 3.1-NC with shTWIST1

Full size image

TFPI2 over-expression inhibited in vivo breast cancer tumor growth

The in vivo xenograft model was conducted via inoculation of Ad-pcDNA 3.1-TFPI2 into nude mice to investigate clinical application of TFPI2 in breast cancer. Elevation of TFPI2 via Ad-pcDNA 3.1-TFPI2 was confirmed in Fig. 6a. Moreover, intratumoral injection of Ad-pcDNA 3.1-TFPI2 inhibited tumor growth and tumor volume (Fig. 6b). Furthermore, the proteins expression of TFPI2 was increased; while the expression of TWIST1 was decreased by Ad-pcDNA 3.1-TFPI2 indicated by immunohistochemistry (Fig. 6c) and western blot (Fig. 6d). Integrin α5 was also down-regulated in mice injected with Ad-pcDNA 3.1-TFPI2 (Fig. 6d). These results revealed that TFPI2 over-expression inhibited breast cancer growth via down-regulation of TWIST1 and integrin α5.

Fig. 6
figure 6

TFPI2 over-expression inhibited in vivo breast cancer tumor growth. a Transfection efficiency of Ad-pcDNA 3.1-TFPI2 in nude mice, suggesting up-regulation in mice injected with Ad-pcDNA 3.1-TFPI2. ** represents Ad-pcDNA 3.1-TFPI2 vs. Ad-pcDNA 3.1-NC, p < 0.01. b Injection of Ad-pcDNA 3.1-TFPI2 inhibited breast cancer tumor growth and volume. * represents Ad-pcDNA 3.1-TFPI2 vs. Ad-pcDNA 3.1-NC, p < 0.05. c Immunohistochemistry analysis of TFPI2 and TWIST1 in tissues of mice intratumoral injected with Ad-pcDNA 3.1-TFPI2 or Ad-pcDNA 3.1-NC, suggesting up-regulation of TFPI2 and down-regulation of TWIST1 in mice injected with Ad-pcDNA 3.1-TFPI2. d Injection of Ad-pcDNA 3.1-TFPI2 promoted on proteins expression of TFPI2, while inhibited TWIST1 and integrin α5 in xenograft tumor mice

Full size image

Discussion

Serine proteases catalyze hydrolytic reactions to participate in important physiological processes, including angiogenesis, apoptosis, wound healing (Jang et al. 2008). Dysregulated serine proteases activities have been implicated in the pathogenesis of various cancers (Lam and Schmidt 2010). Serine protease inhibitors strictly regulate the activity of serine proteases to maintain homeostasis (Rawlings et al. 2004), and have been considered as important cancer biomarkers (Putnam et al. 2003). Kunitz serine protease inhibitors, belonging to canonical serine proteases inhibitors (Krowarsch et al. 2003), are closely involved in tumor progression (Wu et al. 2017; Li et al. 2009; Kobayashi et al. 2000; Liu et al. 2018). As a common Kunitz serine protease inhibitors TFPI2 is involved in various tumor progression, especially in breast cancer. The present study for the first time indicated that TFPI2 suppressed breast cancer progression through inhibiting TWIST-integrin α5 pathway.

In consistent with previous studies (Xu et al. 2013; Guo et al. 2007), TFPI2 was down-regulated in breast cancer tissues. Low expression of TFPI2 was significantly related to tumor size, metastasis and pathological stage of breast cancer patients, which was in line with Cheng et al (Xu et al. 2013). They reported that TFPI2 was related to poor prognosis of breast cancer, suggesting the potential of TFPI2 as a prognostic biomarker for breast cancer. Moreover, in vitro functional assays revealed that over-expression of TFPI2 inhibited cell viability, proliferation, migration and invasion of breast cancer cells, confirming the clinical results of TFPI2 in breast cancer. In vivo subcutaneous xenotransplanted tumor model also revealed that ectopic expression of TFPI2 could suppress in vivo tumorigenic ability of breast cancer. In conclusion, TFPI2 might function as potential prognostic biomarker for breast cancer, and a potential novel target for the breast cancer therapy.

Although TFPI2 has been implicated in progression of various tumors, the exact regulatory mechanisms remain unclear. Epigenetic inactivation via hypermethylation of promoter CpG island of TFPI2 is associated with TFPI2silencing in pancreatic ductal adenocarcinoma (Sato et al. 2005), gastric cancer (Takada et al. 2010), non-small-cell lung cancer (Rollin et al. 2005) and glioblastomas (Vaitkiene et al. 2012), and contributes to the aggressive phenotype of various tumors. More recently, CpG methylation in the TFPI2promoter was also found in breast cancer (Guo et al. 2007). However, the mechanism linking TFPI-2 to breast cancer progression remains unknown. TWIST1 is widely known as EMT-inducing transcription factor that promote cell migration and invasion, and is also shown to be prognostic biomarker for breast cancer (Imani et al. 2016). Knockout of TWIST1 inhibited breast cancer metastasis (Xu et al. 2017b). Therefore, the regulatory mechanism of TFPI2 in breast cancer progression might be associated with TWIST1 expression. The present study showed that TWIST1 was negatively correlated with TFPI2 in breast cancer patients, and the inhibition ability of TFPI2 on breast cancer progression was reversed by over-expression of TWIST1. The effect of TFPI2 on EMT in breast cancer needs to be further investigated.

The underlying mechanism involved in regulation of breast cancer progression via TFPI2-mediated TWIST1 was then determined. Signaling pathways involved in EMT transition, such as Wnt, participated in regulation of TWIST1 on breast cancer (Glackin 2014). In addition, energy metabolism reprogramming pathways, PI3K/AKT and p53, were also involved in promotion of breast cancer via TWIST1 (Yang et al. 2015). Down-regulation of luminal breast cancer marker (Foxa1) and up-regulation of basal-like breast cancer markers (integrin α5 and integrin β1) were regulated by TWIST1 to promote breast cancer progression (Xu et al. 2017a). Our results showed that TFPI2-mediated down-regulation of TWIST1 decreased integrin α5 thereby inhibiting breast cancer progression. However, since integrin α5 and integrin β1 served as important mesenchymal marker to regulate EMT during breast cancer (Nam et al. 2015), the effect of TFPI2-mediated TWIST1 on regulation of integrin β1 also needs to be further investigated. Moreover, focal adhesion kinase (FAK) signaling pathway was involved in integrin α5 (Huang et al. 2016) and integrin β1 (31)-mediated breast cancer metastasis, and integrin α5 and integrin β1 were related to PI3K/Akt signaling (Watabe et al. 2011). The downstream signaling pathway involved in TFPI2/TWIST1/integrin α5 axis in breast cancer progression should also be investigated in the future study.

Conclusion

TFPI2 inhibited TWIST1 expression to down-regulate integrin α5, and TFPI2/TWIST1/integrin α5 axis contributed to suppression of breast cancer progression, suggesting a novel insight into the treatment of the disease.